Abstract:Objective: To investigate the effect of human urinary kallikrein(HUK) on acute cerebral infarction and the relationship between the treatment result and influential factors. Methods: One hundred and twenty patients with acute cerebral infarction were enrolled in the randomized control trail.All patients were randomly divided into treatment group(n=60) and control group(n=60).They were both treated by identical basis therapy.The patients in the treatment group were treated by syringe pumps of 0.15 PNA HUK diluted in 50 mL saline once per day for 21 days.The national institutes of health stroke scale (NIHSS) scores of two groups were analyzed before and after the treatment. All patients were classified according to the trial of org 10 172 in acute stroke treatment (TOAST) classification and oxforshire community stroke project (OCSP) classification. Results: Before treatment, there was no significant difference in the NIHSS scores between the two groups(P>0.05). At the end of treatment, the NIHSS scores in both groups were significantly decreased(P<0.05). Compared with the control group, the treatment group had lower NIHSS scores(P<0.05). The efficacy in the treatment group(81.67%)was better than that in the control group(51.67%). The differences between diabetes, TOAST classification and clinical results were significant(P<0.05). Age, sex, hypertension, heart disease, hyperlipidemia, smoking, drinking alcohol, transient ischemic attack(TIA), progressive cerebral infarction, and OCSP classification had no significant effects on clinical results(P>0.05).The efficacy using HUK to patients without diabetes and non cardiac cerebral infarction was better than the patients with diabetes and cardiac cerebral infarction. Conclusion: HUK is an effective treatment for acute cerebral infarction, especially for acute cerebral infarction patients without diabetes and non cardiac cerebral infarction patients.